Trading Signals: HALO Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Halozyme Therapeutics Inc)
| HALO latest price $41.0300 (5.23%) ($38.7300 - $41.0300) on Wed. Sep. 13, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.26% (three month average) | RSI | 46 | Latest Price | $41.0300(5.23%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | HALO declines -4.2% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HALO advance at 0% a week (0% probability) IVE(60%) XRT(50%) IWM(44%) JNK(42%) ARKG(38%) | Factors Impacting HALO price | HALO will decline at least -1.13% in a week (0% probabilities). INDA(-66%) VXX(-42%) TBT(-33%) OIH(-28%) UUP(-27%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.13% (StdDev 2.26%) | Hourly BBV | 1.6 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $32.11(-21.74%) | Resistance Level | $41.52 | 5 Day Moving Average | $39.02(5.15%) | 10 Day Moving Average | $40.44(1.46%) | 20 Day Moving Average | $41.52(-1.18%) | To recent high | -6.8% | To recent low | 20.9% | Market Cap | $5.608b | | | | Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA. |